Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197781 | 0.89 | TACR1 (0.51) | TACR1CYP3A4CYP2D6CYP2C9EPHX2 | |
| SCHEMBL3988892 | 0.82 | TACR1 (0.53) | TACR1 | |
| SCHEMBL5011932 | 0.82 | TACR1 (0.53) | TACR1 | |
| SCHEMBL5198063 | 0.78 | TACR1 (0.74) | TACR1 | |
| SCHEMBL5199806 | 0.78 | TACR1 (0.74) | TACR1 | |
| SCHEMBL5199801 | 0.78 | TACR1 (0.74) | TACR1 | |
| SCHEMBL4153321 | 0.77 | SPTLC2 (0.48) | TACR1EPHX2 | |
| SCHEMBL6441438 | 0.75 | RHOA (0.51) | TACR1CYP3A4 | |
| SCHEMBL6441435 | 0.75 | RHOA (0.51) | TACR1CYP3A4 | |
| SCHEMBL4154006 | 0.75 | TACR1 (0.60) | TACR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1790636-A1 | PIPERIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20060142337-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142337-A1 | Piperidine derivative and use thereof | AR, AHR, ARNT | TACR1 364/4885CYP3A4 483/4885CYP2D6 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.